MARA G. ASPINALL, President and CEO

Mara Aspinall is President and CEO of On-Q-ity, Inc., an innovative diagnostics company dedicated to improving the treatment of individual cancer patients through real time, non-invasive monitoring to better target therapy and lower costs. On-Q-ity will enable precise personalized therapeutic decisions across multiple cancers through two core proprietary technologies: (1) Microfluidic chip technology that enables the capture, enumeration, and molecular characterization of circulating tumor cells (CTC) in the bloodstream and (2) Validated DNA repair biomarkers that predict treatment response in tissue and blood.

Previously, Mara was President of Genzyme Genetics, a leading provider of testing services in the oncology and reproductive markets. Under her leadership, the company set the standard for industry quality, exhibiting profitable growth at an unprecedented pace. She transformed the business, expanding its scope and market reach to become one of the nation's largest diagnostic laboratories. The company successfully completed and integrated multiple acquisitions, expanded research and development, launched more than two dozen new products and initiated new programs for community outreach and education during her tenure.

Mara has been on the Board of Predictive Biosciences since its inception, serving as Chairman the past year. She is also a Board member of Blue Cross Blue Shield of Massachusetts. Mara is appointed as Lecturer in Health Care Policy at Harvard Medical School and teaches a seminar on medicine and business. During 2008, Mara was on sabbatical from Genzyme working at the Medical School and Dana-Farber Cancer Institute on the implementation of personalized medicine into physician education, clinical practice and research.

Previously, Mara served as President of Genzyme Pharmaceuticals. She restructured the business from generic drug manufacturing to value-added custom production, while building a new international management team that created more than 25% annual profitable growth.

She is an active member of the Federal Secretary of Health and Human Services' Advisory Commission on Genetics, Health and Society as well as a Director of the Personalized Medicine Coalition. Most recently, she co-authored, "Realizing the Promise of Personalized Medicine" in Harvard Business Review.

Bain & Company, an international strategic consulting firm, was where Mara started her business career. She earned her Master of Business Administration from Harvard Business School and her undergraduate degree in International relations from Tufts University.

DANIEL W. PATERSON, Chief Operating Officer

Daniel Paterson is the Chief Operating Officer of On-Q-ity, Inc., an innovative diagnostics company focused on informing and transforming cancer treatment cycle management, improving the quality of life for cancer patients. He leads commercial operations and strategic partnering.

Previously, he was the President and CEO of The DNA Repair Company, an oncology-focused molecular diagnostics company that was acquired by On-Q-ity. With 25 years in the healthcare industry, Mr. Paterson garnered extensive oncology experience accompanied by nearly 20 years in management roles in venture-backed healthcare companies.

Prior to joining The DNA Repair Company, Paterson worked at IMS Health as Head of Global Strategy for Specialty Market and Patient-Level Data. He joined IMS after it acquired PharMetrics where he was Vice President of Marketing and Corporate Development, and before that, Vice President of Sales, Marketing, and Business Development. While at PharMetrics, Paterson was responsible for developing the strategy, product portfolio, and key partnerships, including playing a key role in the company's eventual sale to IMS.

Earlier in his career, Paterson was Vice President of Product Management and Business Development at CareTools, a healthcare information systems company. While there, he oversaw the company's product portfolio and partnership strategy. He was a member of the founding management team for OnCare, an oncology physician practice management company that grew to over $100 million in annual revenue. He was also on the founding management team of Axion, a cancer-focused pharmaceutical and clinical service firm that was rated #4 on the Inc. 500 List of the fastest growing companies in the United States from 1990 to 1995. The company had annual revenues of more than $250 million at the time it was sold to Bristol Myers Squibb.

Paterson began his career designing and managing clinical trials in both industry and academic settings, including a nationwide oncology consortium headquartered at the Dana-Farber Cancer Institute.

He holds a B.S. in Biology from Boston University and attended Northeastern University's graduate pharmacology program.

BRIAN E. WARD, Ph.D., Executive Vice President

Brian Ward, PhD is Executive Vice President of On-Q-ity Inc., an innovative diagnostics company focused on informing and transforming cancer treatment cycle management, and improving the quality of life for cancer patients. He was the Executive Vice President of The DNA Repair Company, when it was acquired by On-Q-ity.

Brian has more than 20 years experience developing, launching and commercializing clinical diagnostic assays in the biotechnology industry. For over a decade, Brian served as head of Operations at Myriad Genetics Laboratories, Inc. He joined Myriad prior to the launch of their first product and was promoted to their Senior VP of Operations as the product grew to over $100 million in annual sales. During his tenure, he was responsible for product development, clinical operations, customer relations, medical sciences, automation, informatics technologies and reimbursement. In all, Brian successfully directed the creation of several clinical laboratories offering a number of innovative clinical diagnostic and forensic tests. Each of these laboratories were successfully inspected, accredited and licensed by all applicable agencies. One of these laboratories had the honor of being asked to be the first commercial laboratory to participate in victim identification following the attack at the World Trade Center on 9/11.

Immediately prior to joining the DNA Repair Company, Brian was the Senior Vice President of Development for Genomic Health, Inc. where he directed product development, program management, automation, manufacturing, the GLP laboratories, developmental oncology and pathology for their breast and colon cancer products.

Previously, Brian created and directed the first cytogenetics laboratory for Genzyme Genetics while acting as Site Manager. In addition to introducing a number of cytogenetic assays, Brian developed and directed four laboratories and supervised the development and clinical launch of an innovative rapid prenatal diagnostic assay.

In addition to his PhD, he is double boarded in Cytogenetics and Molecular Genetics. Brian also has a M.S. in Genetic Counseling, is a Founding Fellow of the American College of Medical Genetics, and has served on the faculty of the University of Colorado Health Sciences Center. He has published over 40 peer reviewed articles and book chapters and has authored over 120 technical abstracts.

GARY PALMER, M.D., J.D., M.B.A., M.P.H., Chief Medical Officer

Dr. Palmer comes to On-Q-ity from Genomic Health, Inc., where he was Vice President of Medical Affairs. At Genomic Health, Dr. Palmer was instrumental in the commercial success of the Oncotype DX Breast Cancer Assay. During his four and a half years there, he worked extensively with thought leaders and insurers to gain widespread acceptance and reimbursement of the Assay. He also developed an effective Medical Affairs group which is now running numerous investigator studies. Assay usage increased ten-fold while he was at Genomic Health. More recently, he has led the medical effort to introduce the Oncotype DX Assay internationally, interacting with multiple European and Asian physicians and spearheading many international studies.

Prior to Genomic Health, Dr. Palmer had extensive experience in the pharmaceutical industry, including roles as Executive Director at Kosan Biosciences and at Salmedix, Inc. where he spent time in early drug development. Previously, he spent five years at Amgen where he was involved in the development and commercialization strategies of Neulasta and Aranesp.

Before his roles in industry, Dr. Palmer served as a medical oncologist in both academia and in the community setting. Dr. Palmer was director of the Medical Breast Service at the University of California, Davis, Cancer Center and Chief of Medical Oncology at the Mercy Health System, Sacramento, California. For the last nine years he has been on the adjunct faculty of the University of California, Davis, Graduate School of Management where he teaches "Management of Biotechnology."

Dr. Palmer is a magna cum laude graduate of Yale University and a graduate of the Stanford University School of Medicine. He did his internal medicine training at the Boston City Hospital and his oncology fellowship at the Massachusetts General Hospital. He has a Masters in Business Administration (MBA) from the University of California, Davis, and a Masters in Public Health (MPH) from U.C.L.A. As well, Dr. Palmer holds a J.D. degree from Concord University and is admitted as an attorney to the State Bar of California.